- Home
- NFJ vs CLDX Comparison
NFJ vs CLDX Comparison
Compare NFJ & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- CLDX
- Stock Information
- Founded
- NFJ 2005
- CLDX N/A
- Country
- NFJ United States
- CLDX United States
- Employees
- NFJ N/A
- CLDX N/A
- Industry
- NFJ Finance: Consumer Services
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NFJ Finance
- CLDX Health Care
- Exchange
- NFJ Nasdaq
- CLDX Nasdaq
- Market Cap
- NFJ 1.2B
- CLDX 1.3B
- IPO Year
- NFJ N/A
- CLDX 2008
- Fundamental
- Price
- NFJ $12.50
- CLDX $22.19
- Analyst Decision
- NFJ
- CLDX Buy
- Analyst Count
- NFJ 0
- CLDX 9
- Target Price
- NFJ N/A
- CLDX $50.00
- AVG Volume (30 Days)
- NFJ 223.5K
- CLDX 852.7K
- Earning Date
- NFJ 01-01-0001
- CLDX 08-11-2025
- Dividend Yield
- NFJ 9.01%
- CLDX N/A
- EPS Growth
- NFJ N/A
- CLDX N/A
- EPS
- NFJ N/A
- CLDX N/A
- Revenue
- NFJ N/A
- CLDX $7,559,000.00
- Revenue This Year
- NFJ N/A
- CLDX N/A
- Revenue Next Year
- NFJ N/A
- CLDX N/A
- P/E Ratio
- NFJ N/A
- CLDX N/A
- Revenue Growth
- NFJ N/A
- CLDX 24.49
- 52 Week Low
- NFJ $10.45
- CLDX $14.40
- 52 Week High
- NFJ $12.86
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- NFJ 46.63
- CLDX 50.42
- Support Level
- NFJ $12.64
- CLDX $21.57
- Resistance Level
- NFJ $12.90
- CLDX $23.41
- Average True Range (ATR)
- NFJ 0.15
- CLDX 1.11
- MACD
- NFJ -0.03
- CLDX -0.16
- Stochastic Oscillator
- NFJ 14.89
- CLDX 24.90
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.